title: [Can the progression of coronary heart disease be modified by calcium antagonists?].
abstract: Experimental atherosclerosis in animals preferentially induced by cholesterol-rich food can be successfully suppressed by calcium channel blocking agents such as verapamil, nifedipin, nicardipin, and diltiazem. The question whether calcium channel blockers can favorably influence atherosclerosis in humans remains a matter of debate. A few observational investigations in the past showed positive results of calcium channel blocker therapy in patients with angiographically proven coronary artery disease (CAD). At present three prospective randomized clinical trials are under way (INTACT-study, FIPS-study, study from the Montreal Heart Institute). Target variable is the severity of coronary atherosclerosis assessed by angiography both at entry into the study and after 2-3 years of treatment. 445 patients after coronary bypass surgery were included in the FIPS study (Frankfurt Isoptin Progression Study) and were randomly allocated to either verapamil 120 mg t.i.d. or placebo treatment. Extent of coronary atherosclerosis, assessed by repeat angiography 1 and 3 years after randomization, is expressed by scores with separate evaluation of non-bypassed vessels, segments distal to the peripheral bypass insertion, bypassed segments and grafts. The 1-year follow-up was completed for 162 patients (Group A = 80 patients; group B = 82 patients). There was a homogeneous distribution in both groups for all clinical variables, graft patency rates (76%/75%), and the incidence of clinical events (myocardial infarct, need for cardiac surgery or PTCA, cardiac death: 5%). The overall progression of atherosclerosis in the first year after bypass surgery was small. Thus, the question of whether calcium channel blockers can retard progression of coronary atherosclerosis cannot be answered before completion of the aforementioned trials.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Abteilung für Kardiologie, Johann Wolfgang Goethe-Universität Frankfurt a. M.
authors.forename: W
authors.initials: W
authors.lastname: Schneider
authors.forename: P
authors.initials: P
authors.lastname: Roebruck
authors.forename: G
authors.initials: G
authors.lastname: Kober
authors.forename: M
authors.initials: M
authors.lastname: Alle
authors.forename: G
authors.initials: G
authors.lastname: Cieslinski
authors.forename: D
authors.initials: D
authors.lastname: Mildenberger
authors.forename: P
authors.initials: P
authors.lastname: Satter
authors.forename: M
authors.initials: M
authors.lastname: Kaltenbach
mesh_terms: D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000473:pathology; D003331:Coronary Vessels / Q000473:pathology; D006801:Humans; D011446:Prospective Studies; D011817:Rabbits; D051381:Rats; D012189:Retrospective Studies
chemical_list: D002121:Calcium Channel Blockers
vernacular_title: Lässt sich mit Kalziumantagonisten die Progression der koronaren Herzkrankheit beeinflussen?